Clinical Trials · NCT05254314
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Enrollment
- 100
- Start date
- Oct 2022
- Locations
- 1 site, United States
- Primary endpoint
- The efficacy of semaglutide on asthma control questionnaire-7 score in subjects with symptoms, persistent asthma and obesity.